Stanton Marshall S. 4
4 · ARTIVION, INC. · Filed Nov 24, 2025
Insider Transaction Report
Form 4
ARTIVION, INC.AORT
Stanton Marshall S.
SVP, Clinical & MD Affair
Transactions
- Sale
Common Stock
2025-11-20$44.14/sh−11,888$524,736→ 44,753 total - Exercise/Conversion
Common Stock
2025-11-20$18.44/sh+2,033$37,489→ 46,786 total - Exercise/Conversion
Stock Options (Right to buy)
2025-11-20−2,033→ 20,301 totalExercise: $18.44From: 2023-02-23Exp: 2029-02-23→ Common Stock (2,033 underlying) - Sale
Common Stock
2025-11-20$44.28/sh−1,355$59,997→ 44,753 total - Exercise/Conversion
Stock Options (Right to buy)
2025-11-20−1,355→ 27,075 totalExercise: $11.03From: 2023-11-08Exp: 2029-11-08→ Common Stock (1,355 underlying) - Exercise/Conversion
Common Stock
2025-11-20$11.03/sh+1,355$14,946→ 46,108 total - Sale
Common Stock
2025-11-20$44.31/sh−2,033$90,092→ 44,753 total
Footnotes (5)
- [F1]Reflects weighted average price. Range of prices were between $43.92 to $44.49. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]Reflects weighted average price. Range of prices were between $44.26 to $44.44. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Reflects weighted average price. Range of prices were between $44.26 to $44.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023.
- [F5]Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.